Perseon Launches INSPIRE 2017, a Dramatic Effort to Increase Adoption of Microwave Ablation to Fight Cancer

Perseon Corporation

("Perseon" or the "Company"), today announced the launch of INSPIRE 2017, a new campaign which is dedicated to the growth and direction of the company over the next three years, particularly in the area of lung cancer, a disease where MicroThermX is better suited to treatment than other energy ablation products due to the system's 915 MHz frequency and synchronous wave alignment technology. INSPIRE 2017 will reinforce the use of energy ablation in an industry where awareness is low, provide economic outcomes highlighting the impact of energy ablation, and continue to provide education to doctors and patients on the benefits of MicroThermX ablation technology. In an effort to expand data supporting MicroThermX, Perseon is initiating five clinical studies in over 110 subjects as well as two non-clinical studies. Additionally, the company is working to provide economic outcomes data via two separate initiatives. The first phase will be conducted with the assistance of current MicroThermX users and shared at an upcoming industry conference in early 2016. The second phase will provide a large scale economic model that will support the use of energy ablation. "Perseon is generating momentum for energy ablation in an effort to raise the awareness of a technology that should be much more widely known and regarded due to its clinical outcomes and economic benefits," said Clint E. Carnell, President and CEO of Perseon. "INSPIRE 2017 is an extension of the company's ongoing engagement with the healthcare community, including physicians, healthcare systems, and patients, who are the reason we strive to continue developing cutting edge, life-saving technologies that fight cancer." MicroThermX is an energy ablation system, which uses targeted microwave energy to treat cancer by ablating (burning) soft tissue with heat alone. Current treatment sites include cancers of the liver, kidney, bone, and lung. Perseon will continue to expand treatment targets to include other potential organs such as the pancreas, uterus, abdomen, and breast.